Hormone-refractory prostate cancer responding to bevacizumab.
Iacobelli
Stefano
S
D000230:Adenocarcinoma / Q000188:drug therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D017211:Treatment Failure
D000726:Androgen Antagonists; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab